


Ask a doctor about a prescription for APIXABAN STADA 2.5 mg FILM-COATED TABLETS
Patient Information Leaflet: Information for the User
Apixaban Stada 2.5 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack:
Apixaban Stada contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent the formation of blood clots by blocking Factor Xa, an important element in the blood clotting process.
This medicine is used in adults:
Do not take Apixaban Stada
Warnings and precautions
Tell your doctor, pharmacist, or nurse before taking this medicine if you have any of these conditions:
Be careful with apixaban
If you need surgery or a procedure that may cause bleeding, your doctor will tell you to temporarily stop taking this medicine for a while. If you are not sure if a procedure may cause bleeding, consult your doctor.
Children and adolescents
This medicine is not recommended for use in children and adolescents under 18 years of age.
Other medicines and Apixaban Stada
Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines.
Some medicines may increase the effects of apixaban and some medicines may decrease its effects. Your doctor will decide if you should be treated with apixaban if you are taking these medicines and if you should be kept under closer observation.
The following medicines may increase the effects of apixaban and increase the possibility of unwanted bleeding:
The following medicines may reduce the ability of apixaban to prevent the formation of blood clots.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
The effects of apixaban on pregnancy and the fetus are not known. You should not take this medicine if you are pregnant. Tell your doctor immediatelyif you become pregnant while taking this medicine.
Breastfeeding
It is not known if apixaban is excreted in human milk. Ask your doctor or pharmacist for advice before taking this medicine during breastfeeding. They will tell you whether to stop breastfeeding or whether to stop or not start taking this medicine.
Driving and using machines
Apixaban has no influence on the ability to drive or use machines.
Apixaban Stada contains lactose and sodium.
This medicine contains lactose. If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially “sodium-free”.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are in doubt, consult your doctor, pharmacist, or nurse.
Dosage
Take the tablet with water. Apixaban can be taken with or without food.
Try to take the tablets at the same time each day to achieve a better effect of the treatment.
If you have difficulty swallowing the whole tablet, talk to your doctor about other possible ways to take apixaban. The tablet can be crushed and mixed with water, 5% glucose in water, apple juice, or apple puree, immediately before taking it.
Instructions for crushing:
If necessary, your doctor may also administer the crushed apixaban tablet mixed in 60 ml of water or 5% glucose in water through a nasogastric tube.
Take apixaban according to the following recommendations:
To prevent the formation of blood clots in hip or knee replacement surgery.
The recommended dose is one apixaban 2.5 mgtablet twice a day. For example, take one tablet in the morning and one in the evening.
You should take the first tablet between 12 to 24 hours after surgery.
If you have had hipsurgery, you will usually take the tablets for a period of 32 to 38 days.
If you have had kneesurgery, you will usually take the tablets for a period of 10 to 14 days.
To prevent the formation of a blood clot in the heart in patients with an irregular heartbeat and at least one additional risk factor.
The recommended dose is one apixaban 5 mgtablet twice a day.
The recommended dose is one apixaban 2.5 mg tablet twice a day if:
The recommended dose is one tablet twice a day, for example, take one tablet in the morning and one in the evening. Your doctor will tell you how long you should continue the treatment.
To treat blood clots in the veins of the legs and in the blood vessels of the lungs
The recommended dose is twoapixaban 5 mgtablets twice a day for the first 7 days, for example, two tablets in the morning and two tablets in the evening.
After 7 days, the recommended dose is oneapixaban 5 mgtablet twice a day, for example, one tablet in the morning and one in the evening.
To prevent blood clots from recurring after 6 months of treatment
The recommended dose is oneapixaban 2.5 mgtablet twice a day, for example, one tablet in the morning and one in the evening.
Your doctor will tell you how long you should continue the treatment.
Your doctor may change your anticoagulant treatment as follows:
Stop taking apixaban. Start treatment with other anticoagulant medicines (e.g., heparin) at the time you would take the next apixaban tablet.
Stop taking other anticoagulant medicines. Start treatment with apixaban at the time you would take the next dose of the other anticoagulant medicine, and then continue as usual.
Stop taking the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to start taking apixaban.
If your doctor tells you to start taking a medicine that contains a Vitamin K antagonist, continue taking apixaban for at least 2 days after your first dose of the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to stop taking apixaban.
Patients undergoing cardioversion
If your heartbeat needs to be restored through a process called cardioversion, take this medicine at the times your doctor tells you to prevent blood clots in the blood vessels of the brain and other blood vessels in the body.
If you take more Apixaban Stada than you should
Tell your doctor immediatelyif you have taken a higher dose of this medicine than prescribed. Take the medicine pack to your doctor, even if there are no tablets left.
If you take more apixaban than the recommended dose, you may increase the risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that can reverse the anti-factor Xa activity may be necessary.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91562 04 20, indicating the medicine and the amount taken.
If you forget to take Apixaban Stada
If you are in doubt about what to do or if you forget to take more than one dose,ask your doctor, pharmacist, or nurse.
If you stop taking Apixaban Stada
Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot may be higher if you stop the treatment too soon.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Apixaban can be administered for three different diseases. The known adverse effects and the frequency at which they occur may be different, and therefore, they are indicated separately below. For those conditions, the most frequent adverse effect of this medicine is bleeding, which can put the patient's life at risk and requires immediate medical attention.
The following adverse effects have been reported when taking apixaban for theprevention of blood clot formationinhip or knee replacement surgery.
Frequent Adverse Effects(may affect up to 1 in 10 people):
Uncommon Adverse Effects(may affect up to 1 in 100 people)
Rare Adverse Effects(may affect up to 1 in 1,000 people)
Unknown Frequency(cannot be estimated from the available data)
The following adverse effects have been reported when taking apixaban toprevent blood clot formationin theheart in patients with irregular heart rhythm and at least one additional risk factor.
Frequent Adverse Effects(may affect up to 1 in 10 people)
Uncommon Adverse Effects(may affect up to 1 in 100 people)
Rare Adverse Effects(may affect up to 1 in 1,000 people)
Very Rare Adverse Effects(may affect up to 1 in 10,000 people)
Unknown Frequency(cannot be estimated from the available data)
The following adverse effects have been reported when taking apixaban totreat or prevent blood clots from recurringin theveins of the legsand in theblood vessels of the lungs.
Frequent Adverse Effects(may affect up to 1 in 10 people)
Uncommon Adverse Effects(may affect up to 1 in 100 people)
Rare Adverse Effects(may affect up to 1 in 1,000 people)
Unknown Frequency(cannot be estimated from the available data)
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton and on each blister, after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Core of the tablet: microcrystalline cellulose, sodium croscarmellose, sodium docusate, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, magnesium stearate.
Coating (Opadry II yellow): hypromellose (2910, 15 mPa·s), lactose monohydrate, titanium dioxide (E171), macrogol (3350), yellow iron oxide (E172).
Appearance of the Product and Package Contents
The film-coated tablets are round, yellow, and biconvex.
They are available in blisters within cartons containing 10, 20, 30, 60, 100 (clinical packaging), 168, and 200 film-coated tablets.
Single-dose blisters are also available within cartons containing 10 x 1, 20 x 1, 30 x 1, 60 x 1, 100 x 1 (clinical packaging), 168 x 1, and 200 x 1 film-coated tablets.
Not all pack sizes may be marketed.
Patient Information Card: information management
Inside the Apixaban Stada package, along with the leaflet, you will find a Patient Information Card, or your doctor may give you a similar card.
This Patient Information Card includes useful information for you and will alert other doctors that you are being treated with apixaban. You should keep this card with you at all times.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Laboratorio STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona)
Spain
Manufacturer
STADA Arzneimittel AG
Stadastrasse 2-18
61118 Bad Vilbel
Germany
or
STADA Arzneimittel GmbH
Muthgasse 36/2
1190 Wien
Austria
or
Clonmel Healthcare Ltd.
Waterford Road
E91 D768 Clonmel, Co. Tipperary
Ireland
or
Centrafarm Services B.V.
Van de Reijtstraat 31 E
4814NE Breda
Netherlands
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany | Apixaban STADA 2.5 mg film-coated tablets |
Austria | Apixaban STADA 2.5 mg film-coated tablets |
Belgium | Apixaban EG 2.5 mg film-coated tablets |
Czech Republic | Apixaban STADA |
Denmark | Apixaban STADA |
Spain | Apixaban STADA 2.5 mg film-coated tablets EFG |
Finland | Apixaban STADA 2.5 mg film-coated tablets |
France | APIXABAN EG 2.5 mg, film-coated tablet |
Hungary | Apixaban Stada 2.5mg film-coated tablet |
Ireland | Apixaban Clonmel 2.5 mg film-coated tablets |
Iceland | Apixaban STADA 2.5 mg film-coated tablets |
Luxembourg | Apixaban 2.5 mg EG film-coated tablets |
Netherlands | Apixaban CF 2.5 mg, film-coated tablets |
Portugal | Apixabano Ciclum |
Romania | Apixaban STADA 2.5 mg film-coated tablets |
Sweden | Apixaban STADA 2.5 mg film-coated tablets |
Slovenia | Apiksaban STADA 2.5 mg film-coated tablets |
Slovakia | Apixaban STADA 2.5 mg |
Date of the last revision of this leaflet:May 2022
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for APIXABAN STADA 2.5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.